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Purpose: The rapid increase in the incidence of precocious puberty in Korea has clinical 
and social significance. Gonadotropin-releasing hormone (GnRH) stimulation test is 
required to diagnose central precocious puberty (CPP), however this test is expensive 
and time-consuming. This study aimed to identify factors that can predict a positive 
response to the GnRH stimulation test.
Methods: Clinical and laboratory parameters, including basal serum luteinizing 
hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2), were measured in 
540 girls with clinical signs of CPP.
Results: Two hundred twenty-nine of 540 girls with suspected CPP had a peak serum 
LH level higher than 5 IU/L (the CPP group). The CPP group had advanced bone age 
(P＜0.001), accelerated yearly growth rate (P＜0.001), increased basal levels of LH 
(P=0.02), FSH (P＜0.001), E2 (P=0.001), and insulin-like growth factor-I levels (P＜0.001) 
compared to the non-CPP group. In contrast, body weight (P＜0.001) and body mass 
index (P＜0.001) were lower in the CPP group. Although basal LH was significantly 
elevated in the CPP group compared to the non-CPP group, there was considerable 
overlap between the 2 groups. Cutoff values of basal LH (0.22 IU/L) detected CPP with 
87.8% sensitivity and 20.9% specificity.
Conclusion: No single parameter can predict a positive response on the GnRH 
stimulation test with both high sensitivity and specificity. Therefore, multiple factors 
should be considered in evaluation of sexual precocity when deciding the timing of 
the GnRH stimulation test.
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Introduction
Precocious puberty is defined as the development of secondary sexual characteristics before 
8 years of age in girls and 9 years of age in boys. Most cases result from inappropriate early 
activation of the hypothalamic-pituitary-gonadal (HPG) axis, termed central precocious 
puberty (CPP)1). Most cases of CPP are idiopathic CPP, which is diagnosed after excluding 
identifiable causes such as brain lesions, tumors, hydrocephalus, or head trauma2). The 
incidence of sexual precocity is increasing rapidly in Korea, and has recently been recognized 
as an emerging issue3). CPP can compromise height potential or result in psychosocial 
disturbances for those affected4,5). It has been reported that early-maturing girls display more 
problem behaviors because of the gap between their and their peers’ physical appearance5). 
Therefore, careful evaluation of pubertal signs, followed by early diagnosis and proper 
treatment, are important for the girls with suspected sexual precocity6). The diagnosis of CPP 
can be made by documentation of early activation of HPG axis in a child with progressive 
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sexual development, accelerated growth rate, and advanced bone 
maturation. Currently, the gonadotropin-releasing hormone 
(GnRH) stimulation test is the standard method used to verify 
the activation of HPG axis7). However, the GnRH stimulation 
test requires multiple blood sampling over long time periods, 
and sometimes, it needs to be repeated multiple times before a 
diagnosis of CPP can be rendered. Therefore, we investigated the 
clinical and laboratory factors that predict positive results on the 
GnRH stimulation test because knowledge of these factors may 
help determine the patient selection and timing for the test.
This study aimed to identify factors that can predict a positive 
response on GnRH stimulation test in girls with suspected 
precocious puberty. Clinical and laboratory characteristics of 
the patients with precocious puberty were analyzed at the time 
of GnRH stimulation test. In addition, the predictive values of 
basal LH, follicle-stimulating hormone (FSH), and estradiol (E2) 
levels for diagnosis of CPP were examined. 
Materials and methods
This study enrolled 540 girls who visited the Pediatric 
Endocrinology Clinic at Severance Children’s Hospital for 
suspected CPP from March 2007 to June 2011. All subjects had 
onset of breast development before 8 years of age, accelerated 
growth rate, and bone age (BA) advancement at least 1 year 
compared to chronological age (CA). GnRH stimulation test was 
performed before 9 years of age. Among all subjects, 124 cases 
performed second GnRH stimulation test at 6-month interval, 
and only the data from last test were included. All subjects 
were evaluated for the following clinical and biochemical 
characteristics, such as pubertal stage, BA, CA, height, height 
standard deviation score (SDS), weight, weight SDS, body 
mass index (BMI, kg/m2), BMI SDS, yearly growth rate, basal 
LH, basal FSH, basal E2, insulin-like growth factor-I (IGF-I), 
IGF-I SDS, IGF binding protein-3 (IGFBP-3), and IGFBP-3 
SDS. In 124 subjects followed up for 6 months for second 
GnRH stimulation test, ratio of increase of BA to increase of 
CA (delta BA/delta CA) was investigated. Breast development 
was determined according to the Marshall and Tanner staging 
system8). BA was determined on the basis of the Greulich and 
Pyle method9), by performing radiography of the left hand and 
left wrist at the GnRH stimulation test. The height, weight, BMI, 
height SDS, weight SDS, and BMI SDS were calculated using 
the Korean children and adolescents’ growth standard10). IGF-I 
SDS and IGFBP-3 SDS were converted from reference values to 
account for CA11). During the GnRH stimulation test, the level 
of LH and FSH were checked just before GnRH administration, 
and then again at 30, 60, 90, and 120 minutes after injection 
of 100 g of GnRH. Serum levels of basal LH and FSH were 
determined using the sequential 2-step immunoenzymatic 
assay (Access hLH, FSH Reagent Pack, Beckman Coulter Inc., 
Brea, CA, USA) with an intra-assay coefficient of variation (CV) 
of 3.5–5.4%, inter-assay CV of 4.3–6.4%, and a lower limit of 
detection of 0.2 IU/L for both gonadotropins. Serum E2 levels 
were measured using the radioimmunoassay (Coat-A-Count 
Estradiol, Siemens, Erlangen, Germany) with an intra-assay CV 
of 4.0–7.0%, inter-assay CV of 4.2–8.1%, and a lower limit of 
detection of 8 pg/mL. Serum IGF-I and IGFBP-3 levels were 
measured by chemiluminescence immunoassay (Liaison IGF-I 
Reagent, Liaison, Atlanta, GA, USA). CPP was diagnosed when 
the peak LH level was ≥5 IU/L on GnRH stimulation test. Other 
endocrine disorders in subjects or the presence of intracranial 
lesions detected by sella magnetic resonance imaging (MRI) 
were excluded. This study was approved by the Institutional 
Review Board of Severance Hospital (No. 4-2013-0377).
Statistical analyses were performed using IBM SPSS ver. 
20.0 (IBM Co., Armonk, NY, USA). Student t-test was used to 
compare the parameters between the groups with positive and 
negative results on the GnRH stimulation test. The receiver 
operating characteristic (ROC) curve analysis was used to assess 
the sensitivity and specificity of the variable factors. P＜0.05 
were considered statistically significant.
Results
1. Comparison of clinical and biochemical characteristics
   between girls with and without CPP 
Of the 540 girls enrolled in this study, 229 had a positive result 
on the GnRH stimulation test and were therefore diagnosed 
with CPP, whereas the remaining 311 girls had a negative result. 
Height SDS was similar in both the CPP and non-CPP groups 
(0.92±0.89 vs. 0.84±0.95, P=0.34). Weight SDS (0.53±0.77 vs. 
0.79±0.89, P＜0.001) and BMI SDS (0.09±0.92 vs. 0.54±1.04, 
P＜0.001) were lower in the CPP group than in the non-CPP 
group. Yearly growth rate was higher in the CPP group than in 
the non-CPP group (8.88±2.91 cm/yr vs. 6.36±2.20 cm/yr, P
＜0.001). BA advancement was higher in the CPP group than in 
the non-CPP group (10.11±0.64 yr vs. 9.74±0.97 yr, P＜0.001), 
but the difference between the BA and the CA (BA–CA) was not 
significant between the 2 groups (1.81±0.63 years vs. 1.78±0.72 
years, P=0.59) (Table 1). Ratio of increase of BA to increase of 
CA (delta BA/delta CA) was not different between the 2 groups 
(1.16±0.94 vs. 0.99±0.85, P=0.43) (Table 1).
Basal LH levels (0.93±1.07 IU/L vs. 0.75±0.61 IU/L, P=0.02) 
and basal FSH levels (3.53±1.84 IU/L vs. 2.06±1.06 IU/L, P
＜0.001) were higher in the CPP group than in the non-CPP 
group (Table 1). However, there was a considerable overlap 
between the 2 groups. Notably, only 45 of the 311 non-CPP girls 
(14.5%) had basal LH levels less than 0.2 IU/L (the minimum 
detectable level) (Fig. 1). In contrast, 20 of the 229 girls with 
CPP (8.7%) had basal LH levels less than 0.2 IU/L (Fig. 1). The 
basal LH/FSH ratio was lower in the CPP group than in the 
non-CPP group (0.36±0.63 vs. 0.47±0.58, P=0.03). Basal E2 level 
(10.59±4.44 pg/mL vs. 9.09±2.93 pg/mL, P=0.001) and IGF-I 
SDS (0.30±0.94 vs. –0.06±0.80, P＜0.001) were higher in the 
CPP group than in the non-CPP group, whereas IGFBP-3 SDS 
was similar between the 2 groups (–0.50±0.98 vs. –0.51±0.89, 
P=0.88) (Table 1).
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2. Regression analysis of clinical and biochemical
   parameters 
The clinical and biochemical parameters considered to be 
related to the results of GnRH stimulation testing (Table 1) 
were adjusted using binary logistic regression analysis. After 
regression analysis, basal FSH (odds ratio [OR], 2.18; 95% 
confidence interval [CI], 1.749–2.708; P＜0.001), yearly growth 
rate (OR, 1.49; 95% CI: 1.3431–1.659; P＜0.001), IGF-I SDS 
(OR, 1.32; 95% CI, 1.002–1.737; P=0.048), and BMI SDS (OR, 
0.58; 95% CI, 0.372–0.899; P=0.015) were significantly related 
to a positive response on GnRH stimulation, whereas basal LH, 
basal E2, and weight SDS were not (Table 2).
3. Determination of cutoff values for basal LH, FSH, 
   and E2 from ROC curves 
The optimal cutoff values for basal LH, FSH, and E2 to 
discriminate between girls with and without CPP were 
determined using ROC curves. The optimal cutoff value of basal 
LH was 0.22 IU/L, with a sensitivity of 87.8% and a specificity 
Table 1. Clinical and biochemical parameters in patients with 
precocious puberty
Characteristic CPP(n=229)
Non-CPP
(n=311) P-value
Height (cm)  132.4±6.4  129.7±7.0 ＜0.001
Height SDS 0.92±0.89 0.84±0.95 0.340
Yearly growth rate (cm/yr) 8.88±2.91 6.36±2.20 ＜0.001
Bone age (yr) 10.11±0.64 9.74±0.97 ＜0.001
Chronological age (yr) 8.30±0.69 7.96±0.91 ＜0.001
BA–CA (yr) 1.81±0.63 1.78±0.72 0.590
ΔBA/ΔCAa) 1.16±0.94 0.99±0.85 0.430
Weight (kg) 29.87±5.02 30.19±5.84 0.510
Weight SDS 0.53±0.77 0.79±0.89 ＜0.001
Body mass index (kg/m2) 16.99±2.05 17.89±2.54 ＜0.001
Body mass index SDS 0.09±0.92 0.54±1.04 ＜0.001
Tanner stage 2.50±0.58 2.29±0.56 ＜0.001
Basal LH (IU/L) 0.93±1.07 0.75±0.61 0.020
Basal FSH (IU/L) 3.53±1.84 2.06±1.06 ＜0.001
Basal LH/FSH ratio 0.36±0.63 0.47±0.58 0.030
Basal estradiol (pg/mL) 10.59±4.44 9.09±2.93 0.001
IGF-I (ng/mL) 270.5±85.6 231.5±71.4 ＜0.001
IGF-I SDS 0.30±0.94 -0.06±0.80 ＜0.001
IGFBP-3 (µg/mL) 2.65±0.53 2.60±0.48 0.300
IGFBP-3 SDS -0.50±0.98 -0.51±0.89 0.880
Peak LH (IU/L) 15.73±13.66 3.25±1.01 ＜0.001
Peak FSH (IU/L) 18.47±7.66 15.98±5.99 ＜0.001
Values are presented as mean±standard deviation.
CPP, central precocious puberty; SDS, standard deviation score; LH, 
luteinizing hormone; FSH, follicle-stimulating hormone; IGF-I, insulin-
like growth factor-I; IGFBP-3, insulin-like growth factor binding 
protein-3.
a)CPP (n=48), non-CPP (n=76).
Table 2. Binary logistic regression analysis of the parameters 
related to GnRH stimulation test results
Variable Odds ratio 95% CI P-value
Weight SDS 0.97 0.571–1.629 0.893
Body mass index SDS 0.58 0.372–0.899 0.015
Yearly growth rate 1.49 1.341–1.659 ＜0.001
Basal LH 1.09 0.833–1.415 0.542
Basal FSH 2.18 1.749–2.708 ＜0.001
Basal estradiol 1.05 0.951–1.150 0.353
IGF-I SDS 1.32 1.002–1.737 0.048
CI, confidence interval; SDS, standard deviation score; LH, luteinizing 
hormone; FSH, follicle-stimulating hormone; IGF-I, insulin-like growth 
factor-I.
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Fig. 1. Results show considerable overlap between the 2 groups. CPP, central 
precocious puberty; LH, luteinizing hormone.
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Fig. 2. The statistically optimal cutoff value of basal luteinizing hormone was 0.22 
IU/L, with a sensitivity of 87.8% and a specificity of 20.9% (area under the receiver 
operating characteristic curve, 0.529).
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of 20.9% (area under the ROC curve, 0.529) (Fig. 2). The cutoff 
value of basal FSH was 2.30 IU/L, with a sensitivity of 76.4% and 
a specificity of 65.9% (area under the ROC curve, 0.78) (Fig. 3). 
The cutoff value of basal E2 was 8.30 pg/mL, with a sensitivity 
of 53.3% and a specificity of 65.6% (area under the ROC curve, 
0.615) (Fig. 4). 
Discussion
CPP is the most common form of precocious puberty and 
often results in adverse effects on both physical growth and 
psychological maturation. Therefore, an early diagnosis followed 
by immediate treatment is essential to improve both the physical 
and mental well-being of girls with CPP. Currently, GnRH-
stimulated LH levels are the gold standard diagnostic biomarker 
of CPP. However, GnRH stimulation testing is expensive, time-
consuming, and often requires repeated tests before a definitive 
diagnosis can be made. To avoid unnecessary testing and patient 
discomfort and to reduce costs, several previous studies have 
attempted to identify clinical and laboratory biomarkers that 
may be used to screen patients with suspected CPP in order to 
guide the proper timing of GnRH testing. 
These studies reported that basal LH levels could alone 
diagnose CPP accurately. LH level could be a useful parameter 
because testing of LH level is simple, entails minimal patient 
discomfort, and is quicker to perform compared to the GnRH 
stimulation test. Neely et al.12) have reported that in 49 girls 
with clinical signs suggestive of CPP, spontaneous LH levels 
correlated strongly with peak stimulated LH levels. Therefore, 
they suggested that LH level could be a useful screening tool for 
CPP. They demonstrated that spontaneous LH levels in excess of 
0.1 IU/L predicted CPP with 94% sensitivity and 88% specificity. 
Moreover, random LH levels in excess of 0.3 IU/L had 100% 
specificity for CPP. Similarly, Houk et al.13) investigated basal LH 
levels in 55 girls with suspected CPP using 2 chemiluminescent 
assays (Delfia, Wallac Oy, Turku, Finland; Architect, Abbott Park, 
IL, USA), and assessed the utility of using a single sample to 
diagnose CPP. They reported that a basal LH cutoff value of 0.83 
U/L in the Delfia assay had a sensitivity of 93% and a specificity 
of 100%, whereas a cutoff value of 1.05 U/L in the Architect 
assay had a sensitivity of 100% and a specificity of 100%. They 
therefore suggested that a single basal LH measurement is 
adequate to document a pubertal state in most—but not all—
girls with CPP. Additionally, Pasternak et al.14) reported that 
a basal LH cutoff value of 0.1 IU/L had a specificity of 94.7% 
and a sensitivity of 64.4%, suggesting that a single basal LH 
measurement is adequate to confirm, but not to refute, the 
presence of CPP.
In our study, basal LH was significantly higher in the CPP 
group than in the non-CPP group. However, only 14.5% of 
non-CPP patients had basal LH levels less than 0.2 IU/L (the 
minimum detectable level), whereas 8.7% of CPP patients 
did, suggesting there was a considerable overlap between 
the 2 groups. Moreover, a basal LH cutoff value of 0.22 IU/L 
determined from ROC curves had a sensitivity of 87.8% and a 
specificity of 20.9%, suggesting that basal LH levels do not have 
a sufficiently high sensitivity or specificity to accurately diagnose 
CPP. Our results also demonstrated that basal FSH, basal E2, 
and the basal LH/FSH ratio do not have predictive value for the 
diagnosis of CPP. A basal FSH cutoff value of 2.30 IU/L and a 
basal E2 cutoff value of 8.30 pg/mL had sensitivities of 76.4% 
and 53.3% and specificities of 65.9% and 65.6%, respectively. The 
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Fig. 3. The cutoff value of basal follicle-stimulating hormone was 2.30 IU/L, with 
a sensitivity of 76.4% and a specificity of 65.9% (area under the receiver operating 
characteristic curve, 0.780).
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Fig. 4. The cutoff value of basal estradiol was 8.30 pg/mL, with a sensitivity of 
53.3% and a specificity of 65.6% (area under the receiver operating characteristic 
curve, 0.615).
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basal LH/FSH ratio is considered to be elevated in girls with 
CPP15). In contrast, our results showed that the basal LH/FSH 
ratio was significantly higher in the non-CPP group than in the 
CPP group, and an appropriate cutoff value for basal LH/FSH 
ratio that had both high sensitivity and high specificity could 
not be determined. Thus, a single laboratory parameter that can 
predict a positive result on GnRH stimulation with both high 
sensitivity and high specificity could not be determined in our 
study. This contradiction to the findings of previous studies 
may relate to the difference in subject numbers between studies. 
A previous study using a larger cohort16) also reported that a 
single basal LH measurement was not adequate to confirm CPP. 
Another large cohort study composed of 803 girls reported that 
a basal LH cutoff value of 1.1 IU/L had a sensitivity of 69.1% and 
a specificity of 50.5%17). These results from large cohort studies, 
including ours, suggest that a single basal LH measurement is 
not specific or sensitive enough to diagnose CPP and should 
therefore not be used as a screening test alone.
Furthermore, we assessed many clinical and laboratory 
parameters that may predict a positive result by GnRH 
stimulation test in this study. We found that BA, yearly growth 
rate, serum IGF-I levels, and IGF-I SDS were higher in girls 
with CPP than in those without CPP, whereas weight SDS, 
BMI, and BMI SDS were lower in girls with CPP. In addition, 
binary logistic regression analysis showed that accelerated 
yearly growth rate, high IGF-I SDS, and low BMI SDS were 
significantly correlated with a positive result on the GnRH 
stimulation test. The most reliable clinical measurement was 
accelerated yearly growth rate, in accordance with the findings 
of a previous study in a large cohort16). However, use of yearly 
growth rate has limitations because at least 3 months are 
required to assess the growth velocity. Furthermore, we could 
not determine a proper cutoff value to diagnose CPP using the 
yearly growth rate. BA advancement and ratio of increase of BA 
to increase of CA also could not be used to diagnose CPP in our 
study because these parameters were observed in both groups to 
the same degree. Several studies have reported that serum IGF-I 
levels were elevated in girls with CPP, suggesting that serum 
IGF-I levels are related to CPP16,18). In our study, we analyzed 
IGF-I SDS to adjust the value according to sex and age using 
reference values from Korean children and adolescents11). Binary 
logistic regression analysis showed that serum IGF-I SDS was 
significantly correlated with CPP, but its predictive value was 
weak. Previous studies have reported that obesity is associated 
with earlier pubertal maturation and therefore might be one 
of the reasons for the general trend towards earlier pubertal 
onset19,20). However, obesity is also reported to be associated with 
early pubertal maturation in girls but delayed pubertal onset in 
boys21), so the exact relationship between obesity and precocious 
puberty is not fully determined. In our study, low BMI SDS 
was significantly correlated with a positive result on the GnRH 
stimulation test. 
In conclusion, the present study demonstrated that girls 
with CPP had an accelerated growth rate, advanced BA, and 
increased basal gonadotropin and IGF-1 levels. We were unable 
to identify one individual biochemical parameter that could 
accurately predict a positive result on the GnRH stimulation 
test. Therefore, we suggest that multiple factors, such as clinical 
findings and basal gonadotropin levels, should be considered 
when evaluating sexual precocity and determining the proper 
timing for GnRH stimulation testing.
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